aTyr Pharma, Inc. (ATYR)
NASDAQ: ATYR · Real-Time Price · USD
4.320
-0.110 (-2.48%)
At close: Feb 21, 2025, 4:00 PM
4.466
+0.146 (3.37%)
After-hours: Feb 21, 2025, 7:49 PM EST
aTyr Pharma Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for aTyr Pharma stock have an average target of 18.6, with a low estimate of 9.00 and a high estimate of 35. The average target predicts an increase of 330.56% from the current stock price of 4.32.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for aTyr Pharma stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 2 | 2 | 2 | 3 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 4 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Initiates $16 | Buy | Initiates | $16 | +270.37% | Feb 18, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jan 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +710.19% | Dec 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +710.19% | Dec 3, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +710.19% | Oct 29, 2024 |
Financial Forecast
Revenue This Year
207.97K
from 353.00K
Decreased by -41.09%
Revenue Next Year
2.91M
from 207.97K
Increased by 1,299.74%
EPS This Year
-0.93
from -0.94
EPS Next Year
-0.82
from -0.93
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 420,000 | 25.6M | 123.9M | |||
| Avg | 207,968 | 2.9M | 38.2M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 19.0% | 12,232.7% | 4,156.3% | |||
| Avg | -41.1% | 1,299.7% | 1,212.1% | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.92 | -0.68 | 0.04 | |||
| Avg | -0.93 | -0.82 | -0.62 | |||
| Low | -0.93 | -0.96 | -1.16 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.